GlassScriptPhysician profile
Brian A Karre
NPI 1932371085
$3,180.15
in general payments reported to CMS, 2019-2025
31 companies · $749 in 2025
The $749 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $132 · 2021: $401 · 2022: $419 · 2023: $344 · 2024: $643 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $482.09 | 2022-2025 | |
| Abbvie INC. | $312.26 | 2019-2025 | |
| Astellas Pharma US INC | $306.81 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $257.77 | 2023-2025 | Myfembree |
| Biogen, INC. | $251.03 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $242.56 | 2021-2025 | Slynd |
| Allergan, INC. | $156.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.41 | 2020-2025 | |
| Hologic Sales and Service, LLC | $134.84 | 2021-2024 | Coolseal Generator, Omni Hysteroscope, Acessa Provu System |
| Coopersurgical, INC. | $119.21 | 2019-2025 | Paragard T 380a |
| Boston Scientific Corporation | $117.19 | 2019 | |
| Ethicon US, LLC | $72.65 | 2021-2022 | |
| Organon LLC | $65.52 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $62.99 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $50.11 | 2019-2023 | Gardasil 9 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $46.91 | 2019-2020 | |
| Pfizer INC. | $43.26 | 2022-2024 | |
| Vertical Pharmaceuticals, LLC | $40.75 | 2019-2020 | |
| Myovant Sciences INC. | $38.21 | 2022 | |
| Avion Pharmaceuticals | $32.43 | 2021-2022 | |
| Octapharma USA, INC. | $24.47 | 2025 | Fibryga |
| Medicem INC. | $22.68 | 2024 | |
| Asensus Surgical, INC. | $21.46 | 2019 | |
| Therapeuticsmd, INC. | $20.74 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.08 | 2019 | |
| Agile Therapeutics, INC. | $20.06 | 2024 | Twirla |
| Olympus America INC. | $19.01 | 2024 | Olympus |
| Amag Pharmaceuticals, INC. | $16.37 | 2019 | |
| Roche Diagnostics Corporation | $15.83 | 2019 | |
| Exact Sciences Corporation | $13.72 | 2023 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Karre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.